Stocks in news: Axis Bank, Mankind Pharma, Bank of Baroda, Laurus Labs, Wipro

Posted on:
Key Points

Private equity firm Bain Capital is likely to sell a minor stake worth Rs 3,700 crore in Axis Bank through a block deal on Wednesday, according to media reports...

Mauritius-based Beige Ltd has sold partial stake in Mankind Pharma through bulk deals on Tuesday..

The investors have sold about 1.44 crore shares or 3.6% stake at Rs 1,832 apiece, taking the deal value to Rs 2,640 crore...

A meeting of capital raising committee of the Bank is scheduled to be held on December 15 to discuss and finalize the quantum of the first tranche of Tier II/Sub debt instruments issue within the Board approved capital raising plan...

Wipro announced that it has entered into a new agreement with RSA, one of the worlds leading general insurance companies to help accelerate RSAs migration to the cloud and build a compliant, secure, and scalable IT infrastructure...

You might be interested in

Bain Capital sells stake worth $448 million in India's Axis Bank

13, Dec, 23

BENGALURU: Private equity firm Bain Capital has sold a $448 million stake in Indian private lender Axis Bank in a block trade on Wednesday, according .

Bain Capital sells 1.1% stake in Axis Bank for over Rs 3,700 cr; FPIs among buyers

13, Dec, 23

This is the second time in 2023 that Bain Capital has sold a stake in the private sector lender. In June, it had sold a 0.7% stake in Axis Bank at an average price of Rs 968 apiece, aggregating Rs 2,178 crore. Prior to this, the private equity firm had sold a 1.2% stake in October 2022.

Ahead of Market: 10 things that will decide D-Street action on Tuesday

20, Nov, 23

The smallcap index ended in the positive even as the advance decline ratio softened to 1.09:1. Nifty on Monday formed a small red candle with minor upper and lower shadows on the daily chart

Mankind Pharma set for stellar debut on Monday, Street sees 8-10% listing premium

07, May, 23

Mankind Pharma's shares are commanding a premium of Rs 100-113 to its issue price of Rs 1,080 in the grey market. Research analysts predict an 8-10% higher opening on the listing day. At Rs 1,080 a share, Mankind Pharma is valued at a price-to-earnings of 30 times its FY22 earnings, valuing the company at Rs 44,000 crore post-IPO. Although Mankind Pharma is the fourth-largest Indian pharmaceutical company in terms of domestic sales, investors are advised to book profits on listing day given the expensive valuations of the stock versus peers.

Ahead of Market: 10 things that will decide stock action on Wednesday

15, Aug, 23

A small positive candle was formed on the daily chart with upper and long lower shadow. Technically, this pattern indicates a formation of high wave type candle pattern. Normally, such high wave formation after a reasonable decline or upside calls for impending trend reversal. Having declined recently, the chances of upside bounce are likely in the coming sessions.

Bulk sales hitch a ride on soaring stock market

20, Aug, 23

A Mint analysis showed that key stakeholders, including promoters, have sold shares worth over ₹1.35 trillion through bulk and block deals during the calendar year so far

Stocks in news: PB Fintech, ZEE, PVR Inox, KFin Tech, Mazagon Dock

18, Dec, 23

Zee Entertainment has sent a letter to Sony Group Corporation requesting an extension of the cutoff to complete the merger.

Stocks in news: Zomato, Star Health, Sun Pharma, Piramal Enterprises

29, Aug, 23

Mio IV Star has sold stake in Star Health, while Fidelity, among other funds, bought shares through bulk deals on Monday.